All In Biotech

Drug Trial Radar · NCT06206408

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

410

Actual

Start

Feb 16, 2024

Primary completion

Oct 22, 2025

Study completion Dec 18, 2025

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia. This study will confirm if fezolintant helps reduce the number of hot flashes in Japanese women going through menopause. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. Before the women are assigned a treatment, they will record information about their hot flashes. Women will either take a lower or higher dose of fezolinetant, or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it. The women will take 2 tablets of the study medicine (lower or higher dose of fezolinetant, or the placebo) once a day for up to 12 weeks. They will either take 1 tablet of fezolinetant (higher or lower dose) and 1 placebo tablet, or they will take 2 placebo tablets. The women will continue to record information about their hot flashes on the electronic device or their smartphone. During the study, the women will visit the study clinic a few times. At each visit they will be asked if they had any medical problems and will use an electronic device at the clinic to answer questions about how the hot flashes affect their daily life. Other checks will include a medical examination, vital signs (temperature, blood pressure and pulse). Some blood and urine samples will be taken for laboratory tests. At some visits, the women will also have an ECG to check their heart rhythm. Women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs. The last clinic visit will be 3 weeks after the women take their final tablets of the study medicine (1 tablet of lower or higher dose of fezolinetant and 1 placebo tablet, or 2 placebo tablets).

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    oral

  • PlaceboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS)Time frame: Baseline and Week 8

Locations

64 sites in 1 country. Site status is shown where the registry gives one.

  • NISHIKAWA Women's Health Clinic

    Sapporo, Japan

  • Chita Kosei Hospital

    Chita-gun, Aichi-ken, Japan

  • Konan Kosei Hospital

    Kōnan, Aichi-ken, Japan

  • Daido Clinic

    Nagoya, Aichi-ken, Japan

  • MEITETSU Hospital

    Nagoya, Aichi-ken, Japan

  • Toyota Kosei Hospital

    Toyota-shi, Aichi-ken, Japan

  • Chiba Aoba Municipal Hospital

    Chiba, Chiba, Japan

  • Aiiku Ladies Clinic

    Funabashi-shi, Chiba, Japan

  • Tsujinaka Hospital Kashiwanoha

    Kashiwa-shi, Chiba, Japan

  • Juno Vesta Clinic hatta

    Matsudo-shi, Chiba, Japan

  • Fukuoka Mirai Hospital

    Fukuoka, Fukuoka, Japan

  • Mori Ladies Clinic

    Fukuoka, Fukuoka, Japan

  • Nishiguchi Clinic Fujinka

    Fukushima, Fukushima, Japan

  • National Hospital Organization Takasaki General Medical Center

    Takasaki-shi, Gunma, Japan

  • Sato Hospital

    Takasaki-shi, Gunma, Japan

  • Sadamori Ladies Clinic

    Hiroshima, Hiroshima, Japan

  • Kotoni Ladies Clinic

    Sapporo, Hokkaido, Japan

  • M's Ladies Clinic

    Sapporo, Hokkaido, Japan

  • Miyanomori Ladies' Clinic

    Sapporo, Hokkaido, Japan

  • Social Medical Corporation Caress Sapporo Caress Memorial Hospital

    Sapporo, Hokkaido, Japan

  • Kosumo Clinic

    Kako-gun, Hyōgo, Japan

  • Mari Women'S Clinic

    Nisinomiya-shi, Hyōgo, Japan

  • JA Toride Medical Center

    Toride, Ibaraki, Japan

  • Tsukuba Urocare Clinic

    Tsukuba, Ibaraki, Japan

  • National Hospital Organization Kanazawa Medical Center

    Kanazawa, Ishikawa-ken, Japan

  • Asahi Clinic

    Takamatsu, Kagawa-ken, Japan

  • Shonan Kamakura General Hospital

    Kamakura, Kanagawa, Japan

  • Kawasakieki Fumi Ladies Clinic

    Kawasaki-shi, Kanagawa, Japan

  • Koukan Clinic

    Kawasaki-shi, Kanagawa, Japan

  • Shinkawasaki Kobiki Womens Clinic

    Kawasaki-shi, Kanagawa, Japan

  • Motomachi Ladies Clinic

    Yokohama, Kanagawa, Japan

  • Women's Clinic LUNA Yokohama Motomachi

    Yokohama, Kanagawa, Japan

  • Rakuwakai Otowa Hospital

    Kyoto, Kyoto, Japan

  • Chieko Yukika Lady's Clinic

    Sendai, Miyagi, Japan

  • Social Medical Care Corporation Hosei-kai Marunouchi Hospital

    Matsumoto-shi, Nagano, Japan

  • National Hospital Organization Beppu Medical Center

    Beppu-shi, Oita Prefecture, Japan

  • Miyabi Uro-Gyne Clinic

    Okayama, Okayama-ken, Japan

  • National Hospital Organization Osaka Minami Medical Center

    Kawachinagano-shi, Osaka, Japan

  • Chayamachi Ladies Clinic

    Osaka, Osaka, Japan

  • Chiharu Clinic

    Osaka, Osaka, Japan

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.